• SFTSV NSs Activate NLRP1/CARD8 Inflammasomes by Disrupting D

  2026-04-24

  Liu et al. (2025) report a novel mechanism by which the SFTSV non-structural protein (NSs) directly activates NLRP1 and CARD8 inflammasomes, bypassing canonical triggers by destabilizing the inhibitory DPP8/9 ternary complex. This discovery clarifies pathogen sensing in innate immunity and suggests new research routes for targeting inflammasome regulation in infection and cancer.

• Translational Leverage: EdU Imaging Kits (Cy3) in S-Phase Re

  2026-04-23

  This article delivers a strategic, evidence-backed perspective on using EdU Imaging Kits (Cy3) to advance translational cell proliferation research. Integrating mechanistic rationale, benchmarking, and direct insights from recent kidney development studies, it provides actionable guidance for maximizing experimental fidelity, with special focus on S-phase DNA synthesis detection and translational bottlenecks. Content is differentiated by bridging core mechanistic advances with protocol-level recommendations and real-world strategic implications.

• N6-Methyl-dATP: Precision Epigenetics for DNA Replication Fi

  2026-04-23

  N6-Methyl-dATP empowers molecular biologists to dissect DNA polymerase selectivity and methylation-driven regulation with unprecedented clarity. Its application streamlines workflows for genomic stability studies and epigenetic modulation, enabling robust troubleshooting and innovation in advanced cancer and antiviral research.

• Ciprofloxacin Potentiates RSL3-Induced Ferroptosis via Mitoc

  2026-04-22

  This study reveals that ciprofloxacin, beyond its antibiotic activity, enhances RSL3-induced ferroptosis in cancer cells by promoting mitochondrial Zn2+ accumulation through the STING1–CAV2 signaling pathway. The mechanistic insights into zinc homeostasis and cell death modulation establish a framework for targeted ferroptosis-based cancer therapies.

• Cisplatin (CDDP): Mechanism, Pyroptosis, and Next-Gen Cancer

  2026-04-22

  Explore how Cisplatin (CDDP) not only induces apoptosis but also triggers pyroptosis in cancer cells, revealing novel opportunities for apoptosis assay design and chemoresistance research. This article uniquely integrates recent pyroptosis insights with advanced experimental strategies, positioning APExBIO's Cisplatin as an indispensable tool in modern cancer research.

• Nintedanib (BIBF 1120): Precision Use in Cancer Research Wor

  2026-04-21

  Nintedanib (BIBF 1120) stands out as a robust triple angiokinase inhibitor, enabling targeted angiogenesis inhibition in cancer and fibrosis models. This article translates advanced experimental protocols, troubleshooting strategies, and key findings from recent glioma research into actionable guidance for laboratories seeking reproducibility and mechanistic clarity.

• Novel Methylene Ziprasidone Dimer Impurity Identified in Zip

  2026-04-21

  A recent study identified and structurally characterized a previously unknown methylene ziprasidone dimer (MZD) impurity in manufacturing batches of ziprasidone hydrochloride. This finding highlights the importance of advanced impurity profiling for maintaining the safety and efficacy of atypical antipsychotic agents, with practical implications for both pharmaceutical quality control and neuroscience research.

• Lipo3K Transfection Reagent: Advancing Gene Expression Studi

  2026-04-20

  Lipo3K Transfection Reagent offers researchers a robust, low-toxicity solution for high-efficiency nucleic acid delivery, even in difficult-to-transfect cells. Its unique enhancer system and proven performance in complex models, like kidney organoids, make it an ideal choice for gene expression and RNA interference workflows requiring precision and reproducibility.

• APOL1 Variants, Splice Isoforms, and APOL3: Mechanisms in Re

  2026-04-20

  This study elucidates how molecular evolution, splice isoforms, and APOL3 interactions shape the cellular effects of APOL1 risk variants, providing new mechanistic insight into their role in trypanolysis and kidney disease. The findings create a more cohesive framework for researchers investigating APOL1-mediated cytotoxicity and potential therapeutic strategies.

• LY2109761: Advancing Translational TGF-β Dual Inhibition

  2026-04-19

  This thought-leadership article unpacks the mechanistic, experimental, and translational promise of LY2109761, a TGF-β receptor type I and II dual inhibitor, for researchers navigating the complexities of cancer progression, therapy resistance, and fibrosis. With critical discussion of Smad2/3 phosphorylation blockade, competitive landscape, and integration of the latest evidence—including the microRNA 424/503 cluster's regulatory role—this piece guides translational teams in leveraging LY2109761 for next-generation discoveries.

• HyperScript™ Reverse Transcriptase: Precision cDNA Synthesis

  2026-04-18

  HyperScript™ Reverse Transcriptase enables robust RNA-to-cDNA conversion even from low-abundance or highly structured RNA, surpassing standard M-MLV enzymes in sensitivity and thermal stability. This article translates cutting-edge research and practical workflows into actionable guidance for qPCR and transcriptomics, with troubleshooting strategies to optimize every step.

• Steroid-Induced Protoplast Lysis: Mechanisms and Antagonists

  2026-04-17

  This study systematically investigates how synthetic antimicrobial steroids induce lysis of bacterial protoplasts, focusing on Sarcina lutea, and explores the protective effects of various stabilizers and antagonists. The findings deepen our understanding of direct steroid-membrane interactions in antimicrobial action, with implications for membrane-targeted drug design and the interpretation of receptor-mediated susceptibility.

• CAF-Mediated Mitochondrial Modulation Drives Chemoresistance

  2026-04-16

  This study reveals how cancer-associated fibroblasts (CAFs) promote chemoresistance in prostate cancer by modulating mitochondrial metabolism via the ANGPTL4-IQGAP1 axis. The findings clarify a paracrine signaling mechanism and highlight new targets for overcoming drug resistance.

• Vardenafil HCl Trihydrate: Reliable PDE5 Inhibition for cGMP

  2026-04-15

  This article provides an evidence-based, scenario-driven guide for using Vardenafil HCl Trihydrate (SKU A4323) in cell viability, proliferation, and smooth muscle assays. Drawing on recent proteomics advances and vendor comparison, it clarifies best practices for PDE5 inhibition assays, highlights the compound’s selectivity and solubility, and guides researchers in robust experimental design.

• Praeruptorin A Inhibits Ferroptosis in Doxorubicin Cardiotox

  2026-04-14

  This study introduces a high-throughput ferrous ion probe screening approach to identify compounds that mitigate doxorubicin-induced cardiomyopathy (DIC) by targeting ferroptosis. The researchers discovered Praeruptorin A as a novel inhibitor of DMT1-mediated iron overload and ferroptotic cell death, offering a new therapeutic avenue for reducing the cardiac side effects of anthracycline chemotherapy.

444 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page